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Abstract  26 
 The modified Glasgow Prognostic Score (mGPS) assigns a numerical value (0-2) 27 
from pre-treatment serum concentrations of C-reactive protein (CRP) and albumin to 28 
predict patient outcome. CRP and albumin were evaluated in 77 untreated dogs with 29 
lymphoma to determine the relationship of mGPS to clinicopathological parameters 30 
and whether it could predict progression-free (PFS) and overall survival (OS) in 31 
treated dogs.  mGPS distribution was significantly associated with clinical stage, 32 
substage b, weight loss, gastro-intestinal disturbances and lethargy at presentation.  33 
On univariate analysis, mGPS was significantly associated with OS and PFS, with 34 
shorter median survival times for mGPS 2 compared to mGPS 0 and 1 combined. 35 
Hypoalbuminaemia significantly reduced OS and PFS, however increased CRP had 36 
no effect. Only clinical stage was significantly associated with OS and PFS on both 37 
univariate and multivariate analysis. mGPS has potential prognostic value for canine 38 
lymphoma , but further studies are needed. 39 
 40 
 41 
 42 
 43 
 44 
  45 
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Introduction  46 
Lymphoma is the most common haemopoietic tumour in dogs, accounting for 83% of 47 
all such malignancies in this species.1   Classification of the disease by cell 48 
morphology, lineage and histological grade using the most recent human World 49 
Health Organisation (WHO) system defines similar B and T cell, low and high grade 50 
subtypes to those in humans.2  Diffuse large B cell lymphoma (DLBCL) is the most 51 
common subtype in both species making the dog a useful comparative model for 52 
human non-Hodgkin lymphoma (NHL).2, 3 53 
 54 
The prognosis for canine lymphoma depends on both histopathological and clinical 55 
features. High grade disease and T cell immunophenotype are often associated with 56 
poor prognosis although low grade T cell lymphomas also occur. 4-6  Expression of 57 
class II major histocompatibility complex and high Ki67 are also negative prognostic 58 
indicators along with clinical features such as higher WHO clinical stage, substage b, 59 
some anatomic locations and the presence of hypercalcaemia.7-11  Different subtypes 60 
of lymphoma respond variably to combination chemotherapy protocols with widely 61 
ranging survival times and disease-free intervals, but a poor response to 62 
chemotherapy is considered to be a negative prognostic indicator.8  Prior treatment 63 
with steroids also negatively affects prognosis.12 64 
 65 
Pre-treatment blood parameters that have been explored as prognostic biomarkers 66 
in canine lymphoma include haematocrit 13, thymidine kinase 14, and serum lactate 67 
dehydrogenase.15  Serum acute phase proteins (APPs) are widely used as 68 
biomarkers in the diagnosis and prognosis of human lymphoid neoplasia, particularly 69 
C-reactive protein (CRP), a positive APP that is increased by interleukin-6 (IL-6) and 70 
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elevated in human patients with NHL.16, 17 CRP is increased in untreated dogs with 71 
lymphoma and has potential as a highly sensitive but non-specific serum 72 
biomarker.18-20 Albumin is a negative APP that decreases in response to 73 
inflammation, injury and disease. Hypoalbuminaemia correlates strongly with the 74 
systemic inflammatory response and weight loss in human cancer patients and is 75 
associated with reduced complete remission (CR) rate and survival time in NHL.21, 22  76 
Hypoalbuminaemia is also reported in canine lymphoma and is associated with 77 
shorter remission and survival time.12, 23 78 
 79 
In human medicine, combined use of several serum biomarkers is considered 80 
preferable to a single biomarker in isolation. In human solid cancers including 81 
lymphoma, scoring systems which combine serum biomarkers of systemic 82 
inflammation (for example the international prognostic index (IPI), prognostic 83 
nutritional index (PNI), neutrophil lymphocyte ratio (NLR), and the Glasgow 84 
Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS)) are used to 85 
predict prognosis, guide treatment decisions and improve patient outcomes.24-30  In 86 
contrast, no veterinary prognostic scoring systems are currently in routine use for 87 
canine lymphoma, Although one study evaluated NLR in 77 dogs with multicentric 88 
lymphoma, it was not found to be of prognostic value.31  89 
 90 
Of the above prognostic scores, GPS and mGPS (based on CRP and albumin 91 
concentrations), are reliable independent prognostic factors in human lymphoid 92 
neoplasia 26-29, 32  and we hypothesised that they may also be useful for canine 93 
lymphoma patients. Both scoring systems assign a score of 0 (when both 94 
parameters are within normal range), or 2 (both outside normal range). In the GPS, a 95 
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score of 1 can be given for either low albumin or high CRP, however, with mGPS a 96 
score of 1 is only assigned for high CRP (normal albumin) and a patient with 97 
hypoalbuminaemia but normal CRP is given a score of 0 to reflect the observation 98 
that hypoalbuminaemia without elevated CRP is rare and is not necessarily 99 
associated with poor survival.32, 33  mGPS rather than GPS may therefore be of more 100 
relevance for some tumour types. 33  101 
 102 
The aims of this study were to assign an mGPS to an untreated cohort of dogs with 103 
lymphoma, investigate how these related to patient clinicopathological characteristics 104 
and determine whether mGPS provided prognostic information in dogs that were 105 
treated with chemotherapy. 106 
 107 
Materials and Methods 108 
This prospective study was performed with full ethical approval from the department 109 
of Ethics and Welfare, University of Glasgow with owner consent obtained for 110 
retention of spare serum for CRP analysis. Albumin was assayed in the biochemical 111 
screen for diagnostic purposes.  112 
Dogs 113 
One-hundred and seventy-five dogs with lymphoma that were presented to the 114 
University of Glasgow’s Small Animal Hospital between 2004 and 2010 were eligible 115 
for recruitment onto the study. Inclusion criteria included dogs with a cytological or 116 
histopathological diagnosis of lymphoma with excess serum obtained prior to 117 
treatment, no concurrent infectious or active inflammatory disease, no previous 118 
treatment of lymphoma with surgery or chemotherapy and no steroid treatment in the 119 
last 7 days prior to referral. Diagnosis was confirmed by cytology, histopathology, or 120 
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both, and where possible immunophenotyping was performed using antibodies 121 
against CD3 (T cell) and CD79a (B cell) on cytology or histology slides. Where 122 
possible for the final cohort of dogs, histology and cytology slides were obtained for 123 
retrospective review using the WHO classification 2 and the Updated Kiel 124 
classification respectively.34  Clinical staging was performed on all dogs including 125 
complete blood count, biochemistry analysis, abdominal ultrasonography and 126 
thoracic radiography. Computed tomography (CT) was performed when clinically 127 
appropriate. Splenic and hepatic cytology, bone marrow evaluation, and urinalysis 128 
(including urine protein and creatinine ratio) were performed when deemed clinically 129 
important and when client finances permitted. Chemotherapy treatment with a 25 130 
week CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) multidrug 131 
protocol 35 was offered as the first line treatment to most dogs with high grade 132 
lymphoma. Some dogs received a modified version of this standard CHOP protocol 133 
(eg no L-asparaginase, substitution for doxorubicin if heart disease present), a 134 
different chemotherapy protocol or just prednisolone depending on lymphoma grade, 135 
owner finances and other patient/owner factors.  136 
 137 
Samples 138 
CRP: 1-2 ml of whole blood was collected by jugular venepuncture into plain serum 139 
tubes (Sarstedt AG) as surplus to that required for routine staging. Blood was 140 
allowed to clot for approximately 2 hours at room temperature then separated by 141 
centrifugation (Minispin Eppendorf AG) at 9,000 rpm for 3 minutes. A minimum of 142 
200 µl serum was harvested and frozen at -70°C for analysis at a later date. CRP 143 
was measured using a latex-enhanced immunoturbidimetric assay (Pentra 400, 144 
Horiba ABX, UK) by batch analysis to reduce inter-assay variability. This assay was 145 
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validated to have a low within-run imprecision and intra-assay coefficients of 146 
variance (n=12) of 0.5% and 1.2% at mean control values of 4 mg/l and 30 mg/l of 147 
CRP respectively. This assay also has an acceptable between-run imprecision with 148 
inter-assay coefficients of variance (n=12) of 4.8% and 8.5% at mean control values 149 
of 4 mg/l and 30 mg/l of CRP respectively.  A serum CRP concentration range of 0-150 
10 mg/l was deemed normal based on previous findings by Eckersall et al (1989).36   151 
Albumin: 1.2ml of whole blood was collected by jugular venepuncture into lithium 152 
heparin tubes (International Scientific Supplies Ltd) and routine laboratory 153 
measurements of plasma albumin concentration were carried out on a chemistry 154 
immuno-analyser (AU640, Olympus, USA). The coefficient of variation for this 155 
method, over the range of measurement, was less than 5% as established by routine 156 
quality control measures.  The laboratory reference for plasma albumin 157 
concentration was 29-36 g/l.   158 
 159 
Assigning a Glasgow Prognostic Score and modified Glasgow Prognostic 160 
Score:  161 
Dogs were assigned an mGPS score of 0, 1 or 2 as follows: dogs with both elevated 162 
CRP concentration (>10 mg/l) and hypoalbuminaemia (<29 g/l) were assigned 163 
mGPS 2, dogs with elevated CRP but normal albumin were assigned  mGPS 1 and 164 
dogs with both normal CRP and low or normal albumin concentration were assigned 165 
mGPS 0. 166 
Statistics 167 
Associations between mGPS and clinicopathological features (other than CRP and 168 
albumin) were assessed for all dogs using contingency table analysis with the chi-169 
squared test. Continuous variables were analysed after grouping above/below their 170 
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normal threshold (calcium) or as 3 groups (age, see below).  The influence of mGPS 171 
and other clinical variables on progression free and overall survival was performed in 172 
two groups of patients: Group 1 comprised all dogs that had received treatment i.e. 173 
chemotherapy protocol or steroids-only (n=70) and Group 2 comprised dogs treated 174 
first line with a CHOP-based protocol (n=55) to remove the confounding effect of 175 
other treatment protocols on survival. Univariate regression analysis was performed 176 
using the Cox proportional hazard (Cox PH) model to determine the relationship 177 
between patient characteristics including mGPS and survival. Hazard ratios (HR) are 178 
presented with their 95% confidence interval (CI). All clinicopathological variables 179 
with a p value ≤ 0.1 were included in the final multivariate backward stepwise 180 
regression model and variables were removed from the model when p≥ 0.1. To 181 
increase group sizes and statistical power for the final analysis, mGPS 0 and 1 182 
(mGPS 0+1) were combined and compared to mGPS 2, WHO stage II-IV were 183 
combined and compared to stage V, and age 0-3 and >3-7 years were combined 184 
and compared to > 7 years. Progression-free survival (PFS) was defined as the 185 
period from first day of treatment to day of progression or relapse of disease.  Dogs 186 
were censored at date of last known follow-up or at statistical analysis if progression 187 
had not been reached. Overall survival (OS) was defined as the time from first day of 188 
treatment to day of death and dogs were censored as described for PFS. Univariate 189 
survival analysis was also performed on all categorical variables using the Kaplan-190 
Meier (KM) method, and differences were assessed by means of the log-rank test. 191 
Median survival times for PFS and OS are presented with their 95% CI. The median 192 
values for clinicopathological characteristics are presented with their interquartile 193 
range (IQR).  Analyses were performed using SPSS Statistics Version 22 (IBM 194 
Corp., UK). Statistical significance was set at p ≤0.05.    195 
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 196 
Results 197 
Seventy-seven dogs fulfilled the inclusion criteria. Twenty-four breeds were represented, the 198 
most common being Labrador Retrievers (14 [18%]), Boxers (7 [9%]), Bullmastiffs (6 [8%]), 199 
Golden Retrievers (5 [6%]) and German Shepherd Dogs (5 [6%]). Thirteen dogs (17%) were 200 
crossbreeds. The median age of the dogs at diagnosis was 7.3 years (IQR 3.1). Fifty-three 201 
dogs (69%) were male (30 entire, 23 neutered) and 24 dogs (31%) were female (9 entire, 15 202 
neutered).   203 
Sixty-five dogs (84%) had high grade and 12 (16%) had low grade lymphoma. 204 
Immunophenotyping was performed for 70 dogs: 34 (44%) were B cell and 36 (47%) were T 205 
cell. Pathology review was possible for 50 dogs (5 histology, 45 cytology); the most common 206 
WHO classification was T cell high grade anaplastic large cell lymphoma (4/5 dogs) and the 207 
most common updated Kiel classification was B cell high grade centroblastic polymorphic  208 
lymphoma (17/45 dogs). Two dogs (4%) were stage II, 15 (19%) were stage III, 28 (36%) 209 
were stage IV, and 31 (40%) were stage V. Fifty-four dogs (70%) were classified as WHO 210 
substage b, and 23 (30%) were classified as substage a. The most common presenting 211 
signs were gastrointestinal (GI) disorders including inappetance, anorexia, vomiting, 212 
diarrhoea, and haematochezia (37 [48%]), lethargy (27 [35%]), weight loss (24 [31%]), 213 
polyuria and polydipsia (PU/PD; 13 [17%]), and pyrexia (5 [7%]). At presentation, 10 dogs 214 
(13%) were hypercalcaemic (>3mmol/l).  215 
Of the 77 dogs, 7 (9%) received no treatment, 5 (6%) were treated with prednisolone only, 216 
and 65 (83%) were treated with a multi-drug chemotherapy protocol (55 with a CHOP-based 217 
protocol, 4 with a lomustine-based protocol, 5 with a COP (vincristine, cyclophosphamide 218 
and prednisolone) protocol, and 1 with chlorambucil and prednisolone). Of the 51 dogs that 219 
relapsed, 11 (22%) were given no further treatment, 2 (4%) were treated with prednisolone 220 
only, and 38 (74%) went onto receive a rescue chemotherapy protocol (15 with a CHOP-221 
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based protocol, 11 with a lomustine-based protocol, 10 with single agent L-asparaginase, 1 222 
each with single-agent doxorubicin and cyclophosphamide). The median PFS (using the KM 223 
method) for all treated dogs (Group 1, n= 70) was 91 days (95% CI 60-122 days) and for 224 
CHOP treated dogs (Group 2, n=55) was 115 days (95% CI 58-172 days). Seventy-four out 225 
of 77 dogs (96%) died/were euthanased during the study period, 70 of which were directly 226 
related to the lymphoma or treatment, and 4 dogs died of intercurrent diseases whilst 227 
lymphoma was in complete remission (1 osteosarcoma, 1 primary immune-mediated 228 
thrombocytopenia, 2 cardiac disease). No dogs were lost to follow-up and 3 dogs (4%) 229 
remained alive at the end of the study period. The median OS for Group 1 was 214 days 230 
(95% CI 136-292 days) and for Group 2 was 232 days (95% CI 160-304 days). The 231 
percentage of all treated dogs surviving to 6, 12 and 24 months was 56%, 30% and 13% 232 
respectively. 233 
Pre-treatment serum CRP concentration ranged from 0.4-273.7 mg/l and was elevated in 65 234 
dogs (84%) with a median concentration of 34.7 mg/l (IQR 45.4). Six dogs were outliers with 235 
markedly elevated CRP concentrations (136, 171.5, 174.7, 184.9, 198.1 and 273.7 mg/l). No 236 
common clinicopathological features were shared by outlying dogs. Pre-treatment albumin 237 
concentration ranged from 10-36 g/L with a median concentration of 29 g/L (IQR 5.5). Thirty-238 
seven dogs were hypoalbuminaemic (< 29 g/L); 14 dogs had severe hypoalbuminaemia 239 
(≤24 g/l), and 2 were outliers with albumin concentrations of 10 and 15 g/l. All dogs with 240 
severe hypoalbuminaemia were WHO stage IV or V and substage b (all presented with GI 241 
signs or weight loss). Both outliers had a high grade T cell lymphoma.  Other possible 242 
causes of severe hypoalbuminaemia such as reduced production due to liver dysfunction or 243 
direct loss due to a protein-losing nephropathy/enteropathy were investigated but in all cases 244 
the hypoalbuminaemia was directly attributable to the lymphoma.  245 
Following allocation of prognostic score, 11 dogs (14%) were mGPS 0, 29 (38%) were 246 
mGPS 1 and 37 (48%) were mGPS 2. All mGPS 1 dogs had elevated CRP and normal 247 
albumin. Differences in mGPS according to patient clinicopathological characteristics are 248 
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shown in Table 1. For the 77 dogs at initial presentation, WHO stage (p=0.002) and 249 
substage (p=0.02) differed significantly across the mGPS groups with a trend towards 250 
advancing stage and substage b with increasing mGPS score.  In agreement with substage 251 
b distribution, weight loss, GI disturbances and lethargy at presentation were significantly 252 
differently distributed (p = 0.007, <0.001 and 0.01 respectively) with more frequent 253 
occurrence as the mGPS score increased.    254 
To test which variables influenced OS, univariate regression analysis using the Cox PH 255 
model was carried out.  Dogs with mGPS 2 were at increased risk of death when compared 256 
to mGPS 0+1 regardless of treatment protocol (Group 1 :HR 0.445 [95% CI 0.268-0.740], 257 
p=0.002; Group 2 :HR 0.525 [95% CI 0.299-0.922], p=0.025), however, the significant effect 258 
of mGPS on OS by univariate analysis was lost on multivariate analysis (Table 2 and 3).  259 
Albumin was also negatively associated with OS when looking at all treated dogs (Group 1: 260 
HR 0.923 [95% CI 0.868-0.981], p=0.010), however despite there being a similar trend, 261 
significance was lost when the CHOP-based group were analysed. CRP showed no 262 
significant association with OS in any analysis. Univariate KM survival analysis using the log-263 
rank test indicated that dogs with mGPS 2 had significantly shorter median OS times 264 
compared to dogs with mGPS 0+1 (p= 0.001 and 0.022 for Groups 1 and 2 respectively, 265 
Figure 1,Table 4). While low albumin as a single biomarker showed a similar negative effect 266 
on OS (p= 0.001 and 0.022 for Groups 1 and 2 respectively, Figure  2, Table 4), elevated 267 
CRP did not significantly influence OS.  The percentage of Group 1 dogs with mGPS 0+1 268 
and mGPS 2 surviving to 6, 12 and 24 months was 71% and 38%, 45% and 13%, and 18% 269 
and 6% respectively.  270 
Other variables affecting OS on Cox PH included WHO stage (Group 1 and 2; p= 0.004 and 271 
0.015 respectively) and immunophenotype (Group 2 only, p=0.004) with both retaining 272 
significance within the final multivariate model (Tables 2 and 3).  Pyrexia at time of initial 273 
presentation was also significant in the final multivariate model for Group 1 (Table 2). 274 
Consistent with the regression analysis, KM analysis (Table 4) indicated shorter OS times for 275 
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dogs that were WHO Stage V compared to II-IV (p= 0.003 and 0.013 for Groups 1 and 2 276 
respectively) and, T cell compared to B cell immunophenotype (p=0.003, Group 2 only).   277 
Univariate analysis of PFS using Cox PH (Tables 2 and 3) showed a significant difference in 278 
the risk of disease progression when comparing mGPS 0+1 to mGPS 2 in Group 1 (HR 279 
0.573 [95% CI 0.347-0.946, p=0.029) and significance was also approached in Group 2 280 
(p=0.058), however, mGPS was not significant in the final multivariate model for either 281 
group. KM survival analysis confirmed that mGPS significantly affected PFS in Group 1 282 
((p=0. 027, Figure 3) and approached significance in Group 2 (p=0.055). Similarly 283 
hypoalbuminaemia significantly affected PFS in Group 1 (p= 0.027, Figure 3) and 284 
approached significance for Group 2 (p=0.055) whereas CRP had no effect in Group 1 and 285 
could not be compared in Group 2 because of small sample size. Other significant variables 286 
influencing PFS on univariate regression analysis (Tables 2 and 3) were WHO stage (p= 287 
0.024 and 0.037 for Groups 1 and 2 respectively), immunophenotype in Group 1 and 2 (p= 288 
0.029and 0.004 respectively) and pyrexia at presentation (no pyrexia compared to pyrexia, 289 
Group 1, p=0.049). Significant differences in median PFS were  also seen using the KM log-290 
rank test (Table 4) in Group 1 and Group 2 for WHO stage (p= 0.022 and 0.034 respectively) 291 
, immunophenotype (p= 0.027 and 0.003 respectively) and pyrexia (p= 0.044, Group 1 only). 292 
Within the final multivariate model WHO Stage (Group 1 and Group 2), and 293 
immunophenotype (Group 2 only) retained significance with pyrexia also reaching 294 
significance for Group 1 (Tables 2 and 3).    295 
 296 
Discussion: 297 
This is the first study evaluating the use of the modified GPS in dogs with lymphoma. 298 
Although the population of dogs was comparable to other studies on canine lymphoma with 299 
respect to age, breed, stage, and percentage of hypercalcaemic cases, the ratio of males to 300 
females was approximately 2:1, there were more substage ‘b’ cases, and the ratio of B:T cell 301 
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tumours was approximately equal rather than predominantly B cell.5  While some studies 302 
have also found higher proportions of males, 8, 11 others have reported more females. 9 The 303 
higher proportion of T cell cases may reflect the higher number of substage ‘b’ cases, and 304 
slightly shorter PFS (2-4 months) and OS (5-10 months) for the treated animals compared to 305 
other studies.4, 7 306 
After assigning mGPS, only 14% of dogs had normal CRP and albumin (score 0), with 307 
almost half (48%) having changes in both CRP and albumin (score 2). In human lymphoma 308 
cohorts, the proportion of patients with mGPS 0 is often larger, ranging from 30.4% 29 in HIV 309 
patients with NHL to 71.5% in the DLBCL subtype. 26  mGPS distribution amongst the 310 
population differed significantly with increasing stage and substage b and with specific 311 
clinical signs such as weight loss, lethargy and GI disturbances.  These findings are 312 
consistent with the expected alterations in the APP, albumin and CRP, which would occur 313 
non-specifically in inflammatory conditions producing such clinical signs or with increased 314 
tumour burden.  An association between more adverse clinical characteristics and 315 
mGPS/GPS has been reported in human extranodal NK/T cell lymphoma 28   and DLBCL. 26 316 
mGPS score  predicted survival of dogs with lymphoma as seen by the percentage of mGPS 317 
2 dogs alive at 12 (13%) or 24 (6%) months which was approximately a third of that for dogs 318 
with mGPS score 0 or 1 (45% and 18% for 12 and 24 months respectively). This was 319 
confirmed by the evaluation of mGPS as a prognostic indicator using either Cox PH 320 
regression or Kaplan–Meier analysis, which showed that mGPS 2 was significantly 321 
associated with OS and PFS for treated dogs, but this was only for univariate and not 322 
multivariate analysis. High mGPS is an independent negative prognostic indicator of OS in 323 
human extranodal natural killer/T-cell lymphoma,28 DLBCL26 and HIV infected NHL, 29 324 
however the association with PFS is less clear. 26, 28  Only clinical WHO stage and 325 
immunophenotype (Group 2) retained significance for OS and PFS in both univariate and 326 
multivariate models, indicating their stronger influence on outcome.  Both stage 8, 12   and 327 
immunophenotype 4, 5, 7  have been previously reported as prognostic indicators for canine 328 
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lymphoma. Although pyrexia at presentation had significant association with OS and PFS for 329 
Group 1 treated dogs (multivariate analysis), it is not clear if this association would be 330 
maintained in a larger cohort of dogs. 7-9  331 
 When the individual APP used to produce the mGPS were evaluated, CRP concentration 332 
did not have any significant association with OS or PFS, however hypoalbuminaemia 333 
significantly shortened OS and PFS for all treated dogs, suggesting this has the greatest 334 
influence on the prognostic score.  The lack of significance on OS and PFS for dogs treated 335 
with a CHOP-based protocol may reflect the smaller number of dogs in this group.  The 336 
finding that mGPS affects OS more consistently than either of the APP used to calculate it 337 
supports the conclusion that prognostic scoring using multiple patient parameters may be 338 
more beneficial than using isolated patient parameters alone.  Although CRP concentration 339 
has prognostic significance for human lymphoma in numerous studies, 16, 17, 37 this has not 340 
yet been reported for canine lymphoma.  There are fewer reports in the literature regarding 341 
albumin concentration and human lymphoma, although one study reported 342 
hypoalbuminaemia in 43% of NHL patients. 38 Hypoalbuminaemia was identified as a poor 343 
prognostic indicator in very old patients with NHL 39 and mucosa–associated lymphoid tissue 344 
lymphoma (MALT) 40 and was predictive of ability to achieve complete response in AIDS-345 
related NHL. 41 Significantly lower albumin concentrations have been reported in dogs with 346 
lymphoma compared to controls in a previous small study,42 and hypoalbuminaemia reduces 347 
remission and survival time in canine lymphoma patients. 12, 23  Although albumin may 348 
decline as part of the systemic inflammatory response, additional factors can contribute to 349 
hypoalbuminaemia such as reduced protein intake or starvation, 43 reduced production as in 350 
severe liver disease,44 as well as losses through the GI tract 45 or kidneys. 46   In all cases in 351 
this study, however, hypoalbuminaemia was directly attributable to the lymphoma itself even 352 
for the outliers with very low albumin.  353 
   354 
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The main limitation of this study is the number of dogs that could be included. CRP is not 355 
currently considered part of a routine minimum clinical database and as such only those 356 
cases where spare serum was harvested were included in the final analysis. In addition the 357 
majority of presenting dogs were mature adults with concurrent inflammatory conditions or 358 
diseases and were therefore excluded from the study. Numbers were further reduced for 359 
statistical analysis when dogs were divided according to clinicopathological characteristics or 360 
treatment protocols etc. making some groups too small for statistical analysis to be carried 361 
out or prone to type II error. Larger numbers within each group would increase the statistical 362 
power to detect differences within the multivariate analysis.  363 
 364 
Conclusion 365 
The mGPS was related to both stage and substage in 77 dogs with lymphoma presented to 366 
an oncology referral service, with more mGPS 2 dogs having higher stage and substage b 367 
disease. mGPS 2 was associated with reduced OS and PFS on univariate but not 368 
multivariate analysis. Although the association with OS and PFS may not be as strong as the 369 
effect of WHO stage or immunophenotype, routine measurement of CRP as well as albumin 370 
to allow mGPS assignment may provide additional prognostic information in canine 371 
lymphoma and appears more useful than each APP on its own. The additional cost of 372 
assays, however, should be balanced against the finding that mGPS was not an 373 
independent prognostic marker in this study. 374 
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Table 1: Relationship of mGPS score to clinicopathologicial characteristics in 77 dogs with untreated 515 
lymphoma 516 
 mGPS 0 
n (%) 
mGPS 1 
n (%) 
mGPS 2 
n (%) 
χ2 
p-value 
Total  (n = 77) 11 (14) 29 (38) 37 (48)  
Age (years)    0.26 
    0-3 0 4 (14) 2 (5)  
    >3-7 5 (36) 12 (41) 10 (27)  
    >7  6 (64) 13 (45) 25 (68)  
Sex    0.17 
    Male  5 (6) 22 (29) 26 (34)  
    Female 6 (8) 7 (9) 11 (14)  
Reproductive Status    0.56 
    Entire 7 (9) 13 (17) 19 (25)  
    Neutered 4 (5) 16 (21) 18 (23)  
Breed    0.45 
    Pedigree 10 (13) 23 (30) 33 (43)  
    Crossbreed 1 (1) 6 (8) 4 (5)  
Grade    0.93 
    High 9 (82) 25 (86) 31 (84)  
    Low 2 (18) 4 (14) 6 (16)  
Immunophenotype    0.20 
    B cell 5 (46) 17 (59) 12 (32)  
    T cell 5 (46) 11 (38) 20 (54)  
WHO Stage    0.002 
    II-III 6 (54) 10 (35) 2 (5)  
    IV 1 (10) 12 (41) 15 (41)  
    V 4 (36) 7 (24) 20 (54)  
WHO Substage    0.02 
    a 7 (64) 10 (35) 7 (19)  
    b 4 (36) 19 (65) 30 (81)  
Presenting signs     
     Weight loss 0 2 (3) 12 (16) 0.007 
     GI disturbances 0 11 (14) 26 (34) <0.001 
     Lethargy 0 9 (12) 18 (23) 0.01 
     Pyrexia 2 (3) 0 3 (4) 0.32 
     PU/PD 1 (1) 6 (8) 6 (8) 0.67 
Calcium (mmol/l)    0.06 
    ≤ 3.0 11 (100) 22 (76) 34 (92)  
    > 3.0  0 7 (24) 3 (8)  
Albumin (g/l)    NA 
    ≥ 29 11 (100) 29 (100) 0  
    < 29 0 0 37 (100)  
CRP (mg/l)    NA 
    ≤ 10 11 (100) 0 0  
    > 10 0 29 (100) 37 (100)  
 517 
NA – not applicable to perform chi-squared analysis on albumin and CRP as the mGPS score is 518 
constructed using these variables  519 
 520 
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Table 2. The relationship between clinicopathological factors and survival using the Cox proportional hazards model in all dogs with lymphoma that received 521 
treatment (Group 1, n=70) 522 
       PFS       OS   
  Univariate  Multivariate  Univariate  Multivariate  
Variable N HR (95% CI) p HR 95% CI p  HR (95% CI) p HR 95% CI p  
Age (0-7 years / >7 years) 29 / 41 0.728 (0.436-1.217) 0.221   0.783 (0.471-1.300) 0.344   
Sex (Female / Male) 21 / 49 1.155 (0.682-1.956) 0.595   0.969 (0.571-1.644) 0.907   
Reproductive status (Entire / Neutered) 34 / 36 0.853 (0.525-1.387) 0.522   1.014 (0.623-1.652) 0.955   
Breed (Pedigree / Crossbreed) 57 / 13 0.922 (0.490-1.733) 0.800   0.920 (0.489-1.732) 0.796   
Grade (Low / High) 12 / 58 1.128 (0.600-2.123) 711   1.025 (0.548-1.919) 0.938   
Immunophenotype (B Cell / T cell)* 33 / 32 0.563 (0.337-0.942) 0.029 NA 0.162 0.617 (0.372-1.026) 0.063 NA 0.331 
WHO Stage (II-IV / V) 42 / 28 0.569 (0.348-0.930) 0.024 0.454 (0.266-0.775 0.004 0.477 (0.290-0.785) 0.004 0.387 (0.217-0.690) 0.001 
WHO Substage (a / b ) 24 / 46 1.034 (0.619-1.727) 0.898   0.795 (0.479-1.319) 0.374   
Presenting signs (Not present / Present) 
      Weight Loss 
      GI signs 
      Lethargy 
      Pyrexia 
      PUPD 
 
57 / 13 
41 / 29 
46 / 24 
60 / 10 
57 / 13 
 
0.621 (0.337-1.146) 
1.143 (0.696-1.879) 
1.202 (0.719-2.010) 
2.136 (1.002-4.554) 
0.918(0.499-1.687) 
 
0.128 
0.597 
0.483 
0.049 
0.782 
 
 
 
 
2.532 (1.148-5.581) 
 
 
 
 
 
 
0.021 
 
0.582(0.312-1.083) 
1.015 (0.617-1.670) 
0.972 (0.581-1.625) 
2.077 (0.978-4.412) 
0.760 (0.411-1.404) 
 
0.088 
0.954 
0.913 
0.057 
0.380 
 
NA 
 
 
2.283 (1.017-5.125) 
 
 
0.856 
 
 
0.045 
 
Calcium nmol/L 70 0.941 (0.565-1.569) 0.816   0.914 (0.516-1.620) 0.759   
Albumin g/L 70 0.936 (0.877-0.999) 0.047 NA 0.490 0.923 (0.868-0.981) 0.010 NA 0.844 
CRP mg/L 70 1.001 (0.995-1.007) 0.715   1.002 (0.997-1.008) 0.423   
mGPS (Score 0+1 / Score 2) 38 / 32 0.573 (0.347-0.946) 0.029 NA 0.379 0.445 (0.268-0.740) 0.002 0.612 (0.351-1.067) 0.084 
The reference category for each variable is the first grouping in parentheses unless otherwise stated. 523 
*Unknown immunophenotype for some patients, n=65 524 
NA – not applicable 525 
HR – Hazard ratio, 95% CI – 95% confidence interval 526 
 527 
 528 
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Table 3. The relationship between clinicopathological factors and survival using the Cox proportional hazards model in all dogs with lymphoma that received 532 
treatment with the CHOP chemotherapy protocol (Group 2, n=55) 533 
       PFS       OS   
  Univariate  Multivariate  Univariate  Multivariate  
Variable N HR (95% CI) p HR 95% CI p  HR (95% CI) p HR 95% CI p  
Age (0-7 years / >7 years) 22 / 33 0.721 (0.402-1.293) 0.272   0.845 (0.471-1.516) 0.573   
Sex (Female / Male) 16 / 39 1.092 (0.598-1.994) 0.776   0.986 (0.538-1.807) 0.964   
Reproductive status (Entire / Neutered) 27 / 28 0.788 (0.456-1.362) 0.394   0.941 (0.545-1.624) 0.827   
Breed (Pedigree / Crossbreed) 45 / 10 0.531 (0.256-1.101) 0.089 NA 0.228 0.591 (0.287-1.219) 0.154   
Grade (Low / High) 10 / 45 1.165 (0.579-2.343) 0.669   1.176 (0.585-2.362) 0.650   
Immunophenotype (B Cell / T cell)* 28 / 25 0.425 (0.238-0.758) 0.004 0.434 (0.241-0.784) 0.006 0.421 (0.234-0.758) 0.004 0.433 (0.238-0.786) 0.006 
WHO Stage (II-IV / V) 31 / 24 0.557 (0.321-0.964) 0.037 0.488 (0.273-0.871) 0.015 0.506 (0.291-0.878) 0.015 0.433 (0.234-0.773) 0.005 
WHO Substage (a / b ) 17 / 38 1.919 (0.508-1.664) 0.781   0.679 (0.366-1.259) 0.219   
Presenting signs (Not present / Present) 
     Weight Loss 
     GI signs 
     Lethargy 
     Pyrexia 
     PUPD 
 
44 / 11 
29 / 26 
35 / 20 
48 / 7 
43 / 12 
 
0.574 (0.292-1.128) 
0.907 (0.524-1.568) 
1.346 (0.758-2.389) 
Not run 
0.848 (0.433-1.625) 
 
0.107 
0.727 
0.311 
 
0.620 
 
NA 
 
 
0.862 
 
 
 
 
0.523 (0.264-1.039) 
0.893 (0.515-1.550) 
1.198 (0.671-2.136) 
Not run 
0.769 (0.400-1.478) 
 
0.064 
0.688 
0.541 
 
0.31 
 
NA 
 
 
 
 
0.629 
Calcium nmol/L 70 1.098 (0.662-1.822) 0.718   1.130 (0.648-1.968) 0.667   
Albumin g/L 70 0.937 (0.869-1.010) 0.090 NA 0.219 0.938 (0.874-1.006) 0.074 NA 0.207 
CRP mg/L 70 0.998 (0.991-1.006) 0.643   0.999 (0.992-1.006) 0.739   
mGPS (Score 0+1 / Score 2) 30 / 25 0.576 (0.326-1.019) 0.058 NA 0.472 0.525 (0.299-0.922) 0.025 NA 0.201 
The reference category for each variable is the first grouping in parentheses unless otherwise stated. 534 
*Unknown immunophenotype for some patients, n=53. 535 
NA – not applicable 536 
HR – Hazard ratio, 95% CI – 95% confidence interval 537 
 538 
 539 
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Table 4: Univariate Kaplan-Meier survival analysis of clinicopathological features and progression-540 
free survival (PFS) and overall survival (OS) using the log-rank test  541 
 Group 1 p-value Group 2 p-value 
Variable N PFS OS  N PFS OS  
Age (0-7 years / >7 years) 29 / 41 0.224 0.340 22 / 33 0.269 0.572 
Sex (Female / Male) 21 / 49 0.590 0.907 16 / 39 0.775 0.964 
Reproductive status (Entire / Neutered) 34 / 36 0.521 0.955 27 / 28 0.392 0.826 
Breed (Pedigree / Crossbreed) 57 / 13 0.800 0.795 45 / 10 0.084 0.148 
Grade (Low / High) 58 / 12 0.707 0.938 10 / 45 0.668 0.648 
Immunophenotype (B Cell / T cell) 33 / 32 0.027 0.059 28 / 25 0.003 0.003 
WHO Stage (II-IV / V) 42 / 28 0.022 0.003 31 / 24 0.034 0.013 
WHO Substage (a / b ) 24 / 46 0.898 0.371 17 / 38 0.781 0.375 
Clinical signs (Not present / Present)   
    Weight Loss 
     GI signs 
     Lethargy 
     Pyrexia 
     PUPD 
 
57 / 13 
41 / 29 
46 / 24 
60 / 10 
57 / 13 
 
0.124 
0.596 
0.482 
0.044 
0.782 
 
0.082 
0.954 
0.913 
0.051 
0.376 
 
44 / 11 
29 / 26 
35 / 20 
48 / 7 
43 / 12 
 
0.102 
0.726 
0.308 
NA 
0.619 
 
0.059 
0.687 
0.540 
NA 
0.428 
Calcium (≤3.0 nmol/L / >3 nmol/L) 61 / 9 NA NA 47 / 8 NA NA 
Albumin (≥29 g/L / <29 g/L)  38 / 32 0.027 0.001 30 / 25 0.055 0.022 
CRP mg/L (≤10 mg/L / >10 mg/L) 11 / 59 0.259 0.995 8 / 47 NA NA 
mGPS (Score 0-1 / Score 2) 38 / 32 0.027 0.001 30 / 25 0.055 0.022 
NA – not applicable for test to be run due to small sample size542 
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Figure Legends 543 
Figure 1 (A and B): Kaplan-Meier survival curves comparing the overall survival (OS) time of 544 
dogs with both mGPS 0 + 1 to dogs with mGPS2, looking at 70 dogs that received any 545 
treatment (Group 1 – A, p = 0.001) and 55 that initially received a CHOP-based protocol 546 
(Group 2 – B, p = 0.022). 547 
Median OS: Group 1 mGPS 0+1 = 295 days (95% CI 200-390 days), mGPS 2 = 92 days 548 
(95% CI 0-195 days); Group 2 mGPS 0+1 = 295 days (95% CI 153-437 days), mGPS 2 = 549 
153 days (95% CI 40-266 days). 550 
 551 
 552 
Figure 2 (A and B): Kaplan-Meier survival curves comparing the overall survival (OS) time of 553 
dogs with normal albumin (≥ 29g/L), to dogs with hypoalbuminaemia (<29g/L), looking at 70 554 
dogs that received any treatment (Group 1 – A, p = 0.001) and 55 that initially received a 555 
CHOP-based protocol (Group 2 – B, p = 0.022). 556 
Median OS: Group 1 ≥ 29g/L = 295 days (95% CI 200-390 days), <29g/L = 92 days (95% CI 557 
0-195 days); Group 2 ≥ 29g/L = 295 days (95% CI 153-437 days), <29g/L = 153 days (95% 558 
CI 40-266 days). 559 
 560 
 561 
Figure 3 (A and B): Kaplan-Meier survival curves comparing the progression-free survival 562 
(PFS) time of 70 dogs that received any treatment (Group 1) for dogs with mGPS 0+1 563 
compared to mGPS 2 (p=0.027), and for dogs with normal albumin (≥ 29g/L) compared to 564 
hypoalbuminaemia (<29g/L, p=0.027). 565 
25 
 
Median PFS: mGPS 0+1 = 111 days (95% CI 72-150 days), mGPS 2 = 72 days (95% CI 29-566 
115 days); Albumin ≥ 29g/L = 111 days (95% CI 72-150 days), <29g/L = 72 days (95% CI 567 
29-115 days). 568 
 569 
